• In early August 2026, Prestige Consumer Healthcare reported fiscal 2027 first‑quarter results showing revenue of US$265.71 million, up from US$249.53 million a year earlier, while net income fell to US$29.18 million and diluted EPS from continuing operations declined to US$0.61.
• Following these results, the company raised its fiscal 2027 outlook, lifting expected revenue to US$1.29 billion–US$1.32 billion and guiding GAAP diluted EPS to US$4.18–US$4.28, largely reflecting the addition of the Breathe Right and LaCorium Health businesses despite ongoing Clear Eyes supply constraints.
• Next, we’ll examine how the upgraded full‑year revenue and EPS guidance, driven by recent acquisitions, reshapes Prestige Consumer Healthcare’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Prestige Consumer Healthcare Investment Narrative Recap

To own Prestige Consumer Healthcare, you need to be comfortable with a story built around steady over the counter brand demand, improving supply for key products, and disciplined capital allocation. The latest quarter showed modest revenue growth but a sharp drop in earnings, while the upgraded fiscal 2027 guidance leans heavily on new acquisitions. In the near term, the main catalyst is integrating Breathe Right and LaCorium into the portfolio, with Clear Eyes supply constraints still a central operational risk. Overall, this news does not materially change that risk balance.

The most relevant update here is Prestige raising its fiscal 2027 revenue outlook to US$1.29 billion to US$1.315 billion and guiding GAAP diluted EPS to US$4.18 to US$4.28. This higher top line outlook, coming soon after the LaCorium deal closed and on the back of Breathe Right, puts more focus on whether acquired brands can offset ongoing margin pressure and supply challenges, especially in eye care, which remains a sensitive swing factor for the story.

Yet investors should be aware that if Clear Eyes recovery takes longer than expected and keeps shipments below management goals for several years, then...

Prestige Consumer Healthcare's narrative projects $1.4 billion revenue and $274.7 million earnings by 2029. This requires 9.2% yearly revenue growth and about an $84.4 million earnings increase from $190.3 million today.

Uncover how Prestige Consumer Healthcare's forecasts yield a $66.80 fair value, a 22% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$1.4 billion and earnings around US$285 million by 2029, so compared with baseline expectations, they are effectively betting that acquisitions like Breathe Right and LaCorium will be integrated smoothly and eye care execution risk will be contained, but this latest guidance could still shift how you weigh those possibilities.

Explore another fair value estimate on Prestige Consumer Healthcare - why the stock might be worth as much as 22% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Prestige Consumer Healthcare research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Prestige Consumer Healthcare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Prestige Consumer Healthcare's overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.